Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Biopharmaceutics & Drug Disposition|August 10, 2013
Clinical pharmacokinetics, pharmacodynamics, safety and tolerability of darexaban, an oral direct factor Xa inhibitor, in healthy Caucasian and Japanese subjectsTakeshi Kadokura, Makoto Kashiwa, Dorien Groenendaal, et al.
Clinical Pharmacology in Drug Development|April 30, 2016
The pharmacokinetics of darexaban (YM150), an oral direct factor Xa inhibitor, are not affected by ketoconazole, a strong inhibitor of CYP3A and P-glycoproteinDorien Groenendaal, Gregory Strabach, Alberto Garcia-Hernandez, et al.
British Journal of Clinical Pharmacology|May 31, 2012
The pharmacokinetics of darexaban are not affected to a clinically relevant degree by rifampicin, a strong inducer of P-glycoprotein and CYP3A4Dorien Groenendaal, Gregory Strabach, Alberto Garcia-Hernandez, et al.
Journal of Pharmaceutical and Biomedical Analysis|September 17, 2005
On-line coupling of cyclodextrin mediated nonaqueous capillary electrophoresis to mass spectrometry for the determination of salbutamol enantiomers in urineAnne-Catherine Servais, Marianne Fillet, Roelof Mol, et al.
Electrophoresis|March 9, 2010
Influence of the BGE composition on analyte response in CD-mediated NACE-MSAnne-Catherine Servais, Marianne Fillet, Roelof Mol, et al.
Electrophoresis|January 20, 2004
Feasibility of nonvolatile buffers in capillary electrophoresis-electrospray ionization-mass spectrometry of proteinsJonas H C Eriksson, Roelof Mol, Govert W Somsen, et al.
Clinical Pharmacokinetics|May 2, 2015
Pharmacokinetic Drug Interaction Studies with EnzalutamideJacqueline A Gibbons, Michiel de Vries, Walter Krauwinkel, et al.
Electrophoresis|May 24, 2006
Interlaboratory study of a NACE method for the determination of R-timolol content in S-timolol maleate: assessment of uncertaintyRoland Djang'eing'a Marini, Carl Groom, François R Doucet, et al.
Pageof 2